Immunicum seeks approval for a clinical phase I/II-trial in liver cancer

Press release
130430

Immunicum AB (publ), which develops therapeutic cancer vaccines, initiated a clinical phase I/II-trial in renal cell carcinoma in February 2012. The Company has now submitted an application to the Medical Products Agency for permission to start another clinical phase I/II-trial in liver cancer. The study will include a total of 12 patients, and is planned in cooperation with the Transplantation Centre at Sahlgrenska University Hospital in Gothenburg, Sweden, where Dr Magnus Rizell is responsible for the trial. The first patient is expected to be included around the turn of 2013/2014.

- The application has been submitted according to plan and we look forward to starting our second clinical trial. We believe our vaccine, INTUVAX, has potential to help the large number of liver cancer patients that are not diagnosed early enough to possibly be cured by transplantation or surgery, says Jamal El-Mosleh, CEO of Immunicum.

Immunicum's patented vaccine is based on over 30 years of research in the field of transplantation immunology and activates the body's own immune system to attack harmful substances like tumor cells. The Company has recently completed two new share issues, bringing in a total of 30.2 million SEK before issue costs. The shares have been traded since April 22, 2013 at NASDAQ OMX First North under the ticker IMMU.

G&W Fondkommission is chosen as the Company's Certified Adviser. Tel: +468-503 000 50. www.gwkapital.se.

For further information please contact:
Jamal El-Mosleh, CEO of Immunicum, 0703-31 90 51,
jamal.elmosleh@immunicum.com

About Immunicum AB (publ):

Immunicum AB (publ) develops cancer immunotherapies. Its two main groups of therapeutic cancer vaccines, SUBCUVAX(TM) and INTUVAX(TM), and the method of expansion of tumor-specific T-cells (CD70) is based on the Nobel prize awarded discovery of the dendritic cell and its central role in the activation of the specific immune response. Because the raw material consists of dendritic cells from healthy donors, Immunicum's products can be produced in large scale. The vaccines have earlier proven efficacy in animal studies and are now undergoing clinical trials in patients.